Humana’s stock tanks as it cuts 2024 guidance amid soaring medical costs

Breaking News

Humana Inc.’s stock fell 14.5% early Thursday, after the managed care company’s quarterly loss widened amid soaring medical costs and it cut its 2024 profit guidance to almost half what analysts were forecasting.

Louisville, Ky.-based Humana

said it now expects 2024 per-share earnings of about $14.87 and adjusted EPS of about $16.00, while FactSet is expecting $29.14. The company is expecting higher Medicare Advantage costs that battered earnings in the fourth quarter to persist through the year.

Humana posted a loss of $491 million, or $4.42 a share, for the fourth quarter, wider than the loss of $71 million, or 12 cents a share, posted in the year-earlier period.

The company’s adjusted per-share loss came to 11 cents, while FactSet was expecting EPS of 89 cents.

Revenue rose to $26.462 billion from $22.439 billion, ahead of the $25.491 billion FactSet consensus.

The loss reflects additional increases in Medicare Advantage cost trends, which rose on higher-than-expected inpatient utilization, mostly in November and December, along with an increase in non-inpatient trends.

Humana and rivals including UnitedHealth Group Inc.

have invested generously in the government’s Medicare Advantage program for seniors.

Earlier in January, Humana warned that its fourth-quarter medical loss ratio, a measure of premiums paid to cover medical expenses, had climbed to 91.4%, above the 89% expected by analysts.

The company also warned of slower-than-expected Medicare Advantage enrollment growth. The company said it hadn’t been able to offset those expenses with administrative cost cuts and productivity improvements “due to the recency and significance of the latest emerging trends.”

On Thursday, Humana confirmed it expects Medicare Advantage annual membership growth of about 100,000, or 1.8%.

Mizuho said the guidance is likely a worst-case scenario and that it does not expect trends to persist through the year, given the fourth quarter is traditionally a seasonally strong one for healthcare procedures and the lowest earnings period for managed care companies.

“That sets the stocks up for beats and raises throughout 2024 and also provides the company some cushion to navigate through the first year of the three-year phase-in of the Medicare Advantage coding adjustments,” analyst Ann Hynes wrote in a note to clients.

“Depending on what management says on the 9AM conference call, we believe investors will focus on 2025 earnings given the company’s ability to reprice for this above-average 2023 and 2024 high utilization in the 2025 MA bids,” said the analyst who has a buy rating on the stock.

UnitedHealth shares also tumbled last week after the company reported rising medical costs relative to premium revenue in the fourth quarter.

The stock has fallen 20% in the last 12 months, while the S&P 500

has gained 21%.

Original Post

Articles You May Like

Beyond Meat shares soar as company tops quarterly revenue estimates, plans ‘steep’ cost cuts in 2024
Biden executive order aims to protect Americans’ sensitive data from China, Russia
House China chair demands Elon Musk provide SpaceX internet for U.S. troops in Taiwan
Rates Spark: Safer in Bunds Than Treasuries
Broadcom stock rises into record territory after deal to sell its EUC Division for $4 billion to KKR

Leave a Reply

Your email address will not be published. Required fields are marked *